RESEARCH REPORT Dave Levitan The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer.
REVIEW ARTICLE Elgene Lim, Nancy U. Lin;ONCOLOGY Vol. 26 No. 7 This review will focus on the breast cancer subtypes with the highest incidence of breast cancer brain metastases and will characterize differences in the clinical behavior of brain metastases that arise from these different subtypes.
We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.
• Molecular Classification of Diffuse Gliomas
The development of metastatic disease in patients with paraganglioma is an unusual and challenging event. This case report and review describes the specific features of this disease and the multiple therapeutic options.
• An Uncommon Manifestation of an Uncommon Disease
For the past 15 years, most PACS have performed the basic tasks of taking in images, archiving them, sending them to workstations for display, and... More »
The idea of MR spectroscopy has been kicking around almost as long as MR itself. The allure is seductive: a noninvasive biopsy that quantifies in hard... More »
CT is one of the most important of the noninvasive imaging modalities, providing 3D representations of the x-ray attenuation coefficient with... More »
A healthy 24-year-old male presented with a history of several months of poorly localized headaches and blurred vision. MRI of the brain demonstrated a multi-lobulated mass. Based on the radiographic appearance of the mass, what is the most likely diagnosis?
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.
We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.
Although important questions still remain regarding chemotherapy choice, sequence, and dosing, the answers to which will require additional large phase III trials, radiotherapy alone is no longer appropriate therapy for 1p/19q codeleted anaplastic oligodendrogliomas.
Here we present the history, staging system, and treatment of medulloblastoma, reviewing the prognostic value and clinical application of molecular subtyping while highlighting the differences between adult and pediatric disease.
This review will focus on the breast cancer subtypes with the highest incidence of breast cancer brain metastases—HER2-positive breast cancer, and triple-negative breast cancer—and will characterize differences in the clinical behavior of brain metastases that arise from these different subtypes.
The development of metastatic disease in patients with paraganglioma is an unusual and challenging event. This case report and review describes the specific features of this disease and the multiple therapeutic options.
A healthy 24-year-old male presented with a history of several months of poorly localized headaches and blurred vision. MRI of the brain demonstrated a multi-lobulated mass. Based on the radiographic appearance of the mass, what is the most likely diagnosis?
